Given the close association between the NLRP3 inflammasome and inflammatory stimuli, it may be a promising target for treating NAFLD-related inflammation and metabolic abnormalities. This evidence concerns the gene NLRP3 and metabolic dysfunction-associated steatotic liver disease.